Safe use of ribociclib in a patient with HR+/HER2− metastatic breast cancer receiving chronic hemodialysis
Journal of Oncology Pharmacy Practice
Published online on February 19, 2026
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
İntroductionThe standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4/6 inhibitors and endocrine therapy.Case reportIn this case, our aim was to demonstrate the safety and effectiveness of ...
İntroductionThe standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4/6 inhibitors and endocrine therapy.Case reportIn this case, our aim was to demonstrate the safety and effectiveness of ...